Core Insights - Keysight Technologies has launched two new products, the EV2020B and EV2020BE, aimed at enhancing end-of-line testing for electric vehicle (EV) manufacturing and electric vehicle supply equipment (EVSE) [1] Group 1: Product Launch - The EV2020B EV Manufacturing Functional Test Platform is designed for automakers [1] - The EV2020BE EV Manufacturing Functional Test Platform is tailored for EVSE manufacturers [1] Group 2: Market Impact - These solutions provide a scalable and flexible approach to production testing [1] - The new platforms aim to accelerate time-to-market for EV products [1] - The launch is expected to reduce costs associated with production testing [1] - The solutions ensure readiness for manufacturers in the evolving EV market [1]

LONDON, United Kingdom and SANTA ROSA, Calif.: , Oct. 01, 2025 (GLOBE NEWSWIRE) -- InstrumentiX, an award-winning provider of trading infrastructure monitoring and analytics, today announced that Keysight Technologies, Inc. (NYSE: KEYS), a global technology leader in design, test and network visibility solutions, has acquired a strategic stake in the company. Keysight’s targeted investment underscores InstrumentiX’s market-leading innovation and deepens the companies’ strategic partnership, accelerating dev ...

Core Insights - Keysight Technologies, Inc. has launched the WirelessPro 3GPP AI Simulation Platform, a next-generation software platform aimed at wireless communication system engineers [1] - The new platform provides a unified environment for modeling, prototyping, and validating advanced wireless technologies [1] - WirelessPro features deep integration of AI/ML capabilities and aligns with the latest third-generation partnership standards [1]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Sty ...

Core Insights - Keysight Technologies will showcase 20 advanced AI-enabled 6G and wireless solutions at the India Mobile Congress 2025, aimed at accelerating innovation in 6G and wireless communication systems [1][2] - The event will take place from October 8-11, 2025, at the Yashobhoomi venue in New Delhi, India [1] Technology Demonstrations - **mMIMO Design**: Keysight will demonstrate advanced mMIMO design capabilities across frequency ranges FR1 to FR3, including new sub-THz bands, facilitating faster speeds and wider bandwidths for future wireless technologies [2] - **5G Interference Mitigation**: The demonstration will include advanced spectrum monitoring and AI-driven analytics to optimize spectrum usage and validate network robustness against interference [2] - **NTN Design Optimization**: This demo will focus on satellite-to-terrestrial integration, addressing challenges like propagation delays and dynamic channel conditions to enhance performance for 5G-advanced and 6G NTN deployments [2] - **RF Environment Emulation**: Keysight will recreate real-world wireless conditions in a lab setting, allowing for testing under complex scenarios to ensure reliable performance and reduce field testing costs [2] - **Device Security Defense**: The demo will integrate various testing methods to expose vulnerabilities in wireless and cloud layers, enhancing device resilience against cyberattacks [2] - **Digital Twins Emulation**: This solution will provide scalable modeling of devices and networks, enabling end-to-end validation and optimization of performance across 5G-advanced and 6G [2]

Core Insights - VIAVI Solutions Inc. is recognized as a promising low-priced technology stock, focusing on enhancing its position in network performance and cybersecurity [1] - The company has partnered with CrowdStrike to integrate its Observer platform with Falcon Next-Gen SIEM, aiming to provide unified visibility for enterprises [2] Strategic Developments - VIAVI's growth outlook is supported by strategic mergers and acquisitions, including the acquisition of Spirent Communications' assets, which has led to an upgrade from Morgan Stanley [3] - The price target for VIAVI has been raised from $9.30 to $11, reflecting confidence in the company's growth potential [3] Market Positioning - The acquisition of Ethernet and network security business lines from Keysight Technologies is expected to enhance VIAVI's capabilities in channel emulation and technology testing [4] - Despite some risks, demand from sectors such as aerospace, defense, and data centers provides a counterbalance to potential challenges [4] Company Overview - VIAVI Solutions provides network test, monitoring, and assurance solutions across various sectors, including telecommunications, cloud, and military [5]

Core Viewpoint - Keysight Technologies Inc. reported strong Q3 fiscal 2025 results, with both revenue and net income exceeding estimates, driven by growth in AI data-center markets and defense sectors [2][3][4]. Financial Performance - Net income on a GAAP basis was $191 million or $1.10 per share, down from $389 million or $2.22 per share in the same quarter last year [3]. - Non-GAAP net income was $297 million or $1.72 per share, compared to $275 million or $1.57 in the prior-year quarter, surpassing the Zacks Consensus Estimate by 4 cents [3]. - Quarterly net sales increased to $1.35 billion from $1.22 billion year-over-year, exceeding guidance [4]. Revenue Breakdown - Communication Solutions Group (CSG) generated $940 million in revenues, an 11% increase from $847 million in the prior year, driven by demand for AI data-center network solutions [5]. - Electronic Industrial Solutions Group (EISG) revenues rose to $412 million from $370 million, supported by investments in AI-driven technologies [6]. - Region-wise, Asia-Pacific revenues were $569 million, up from $496 million, while revenues from the Americas increased by 13% to $566 million; European revenues decreased by 2% to $217 million [7]. Profitability Metrics - Non-GAAP gross profit was $864 million with gross margins of 63.9%, compared to $781 million and 64.1% in the prior year [8]. - Non-GAAP operating margin was 25%, up from 24.4% year-over-year; CSG's margin was 26.1%, while EISG's margin improved to 22.3% [8]. Cash Flow and Liquidity - Keysight generated $322 million in cash from operating activities, up from $255 million a year ago; as of July 31, 2025, the company had $2.63 billion in cash and cash equivalents [9]. Future Outlook - For Q4 fiscal 2025, Keysight expects revenues between $1.37 billion and $1.39 billion, with non-GAAP earnings per share estimated between $1.79 and $1.85 [10]. - There has been an upward trend in estimates revisions for the stock, indicating positive investor sentiment [11][13]. Investment Scores - Keysight has a Growth Score of B and a Momentum Score of A, with an aggregate VGM Score of B, indicating a balanced investment profile [12].

Group 1 - Keysight Technologies will showcase data center infrastructure solutions for AI/ML applications at ECOC 2025 [1] - The event will take place from September 29 to October 1, 2025, at Bella Centre in Copenhagen, Denmark [1] - Keysight will present optical test innovations at their booth C2120 [1]

SANTA ROSA, Calif.--(BUSINESS WIRE)--Keysight Technologies, Inc. (NYSE: KEYS) introduces two new millimeter-wave frequency extender modules, the NA5305A Frequency Extender up to 170 GHz and NA5307A Frequency Extender up to 250 GHz, and the 85065A Precision Calibration Kit 0.5 mm. When used with Keysight's PNA/PNA-X Vector Network Analyzers (VNA) and the N5292A Test Set Controller, the new accessories enable engineers to achieve fully calibrated single-sweep broadband S-parameter measurements fr. ...

EMVision Medical Devices (ASX:EMV) Update Summary Company Overview - EMVision Medical Devices is transitioning from an R&D-focused entity to a commercialization-focused company, with over $50 million invested in technology development over the past seven years [1][2] - The company has two main products: the EMU™ device for in-hospital use and the First Responder scanner for ambulance deployment [2] Product Details - **EMU™ Device**: A cart-based system designed for rapid neurodiagnostic capabilities, currently undergoing pivotal study for FDA De Novo clearance [2] - **First Responder Scanner**: An ultra-lightweight helmet designed for road and air ambulance use, facilitating earlier triage and treatment decisions [2] Market Opportunity - The incidence of strokes is increasing, with one in four adults experiencing a stroke in their lifetime, leading to significant health economic impacts estimated at $890 billion in 2021, projected to grow to $1.6 trillion by 2050 [4] - Effective treatments exist but are time-sensitive, with only one in three patients receiving timely interventions [7][8] Clinical Studies and Collaborations - Completed a successful multi-site pre-validation study (EMView) in Australia, leading to confidence in progressing to pivotal studies [2][13] - Collaborations with key industry partners, including the Australian Stroke Alliance and Keysight Technologies, which is also a major shareholder [3][16] Regulatory Strategy - Targeting FDA De Novo submission followed by CE mark submission for European clearance [24] - Engaging in continuous innovation studies to enhance product performance and expand indications, including traumatic brain injury [28] Financial Overview - Revenue model includes capital equipment sales, consumables, and service contracts, with expected pricing for the EMU™ device around $175,000 and the First Responder scanner between $15,000 and $100,000 [22][23] - The company has a strong track record in securing non-dilutive grants, totaling approximately $27 million [42] Market Launch Strategy - Focused on a phased launch in the U.S. stroke belt region, targeting high-volume stroke centers and critical access hospitals [29][30] - Plans to build credibility and trust through direct engagement with the clinical community before scaling operations [31] Reimbursement Strategy - Exploring multiple reimbursement programs to foster adoption, including the New Technology Add-on Payment (NTAP) program [32][33] - Aiming to generate post-approval data to support reimbursement and market adoption [35][36] Future Outlook - Anticipated catalysts include updates on pivotal trials, regional benefits studies, and ongoing collaborations with top-tier institutions [41] - The company is well-positioned to address unmet needs in stroke care with its innovative products and strong clinical evidence [38][39]